{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tofacitinib",
    "query": {
      "intervention": "tofacitinib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 132,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tofacitinib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T20:13:56.126Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02299297",
      "title": "Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-01",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-07",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299297"
    },
    {
      "nct_id": "NCT03772145",
      "title": "Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 103,
      "start_date": "2018-11-27",
      "completion_date": "2024-01-29",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03772145"
    },
    {
      "nct_id": "NCT06923228",
      "title": "A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis (AD)"
      ],
      "interventions": [
        {
          "name": "CGB-500 Ointment with 1% tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib 1.5% Cream QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CAGE Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2025-04-21",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06923228"
    },
    {
      "nct_id": "NCT02566967",
      "title": "An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Norman B. Gaylis, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-05",
      "completion_date": "2018-03-20",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "Aventura, Florida",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02566967"
    },
    {
      "nct_id": "NCT05576051",
      "title": "To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "patterns of use of combination therapy and monotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9159,
      "start_date": "2015-06-04",
      "completion_date": "2015-10-07",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05576051"
    },
    {
      "nct_id": "NCT00784719",
      "title": "A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "CP-690,550 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-04-09",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784719"
    },
    {
      "nct_id": "NCT01059864",
      "title": "Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2010-02",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2012-12-13",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059864"
    },
    {
      "nct_id": "NCT02831855",
      "title": "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 694,
      "start_date": "2016-09-01",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 59,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02831855"
    },
    {
      "nct_id": "NCT05638932",
      "title": "Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aetion, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1442,
      "start_date": "2020-06-16",
      "completion_date": "2023-09-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05638932"
    },
    {
      "nct_id": "NCT03910543",
      "title": "Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Sarcoidosis",
        "Granuloma Annulare"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 5 mg twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-04-11",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-09-05T20:13:56.126Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03910543"
    }
  ]
}